Introduction: Valproic acid is an older-generation antiepileptic drug. It has been implicated in liver-related adverse effects. Methods: This is a retrospective study carried out by collecting non-cutaneous reactions linked to Antiepileptic drugs notified to the pharmacovigilance center of Sfax over 9 years. A pharmacovigilance survey was performed according to the French Begaud imputability method. The plasma determination was carried out by an immune-enzymatic method using an INDIKO device in the pharmacology laboratory of the Faculty of Medicine. Results: We collected 8 cases of hepatic cytolysis with varying severity: 1 case of moderately severe cytolysis (case 1), 1 case of fatal cytolysis (case 8) and 6 cases of benign cytolysis (case 2-7). We stopped the administration of this antiepileptic drug in cases 1, 2 and 8 in the face of high transaminase levels ≥ 5 times the upper limit of normal with a favorable outcome for cases 1 and 2 and fatal for case 8. A dosage was requested in the other cases. For cases 3, 4 and 5, the dosage result was within the therapeutic range with associated digestive intolerance. The approach was to avoid this antiepileptic drug with a good outcome. For cases 6 and 7, the result was close to the upper limit of normal, hence a reduction in the dose of valproic acid was recommended with good progress. Conclusion: The management of valproic acid-related hepatic cytolysis depends on their severity, the results of the plasma valproic acid assay and the results of the etiological assessment.
Bouaziz et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: